Dimerix Cash More Than Doubles as Licensing Payment and Funding Facility Bolster Trial Runway
DXB: $0.215 +4.88% · MC: $120M
Dimerix's cash rose to approximately $35 million at the end of September from $16 million three months earlier, after it received an approximately $14 million upfront licensing payment and drew $17 million from a $34 million funding facility. The company says it has sufficient funding to complete the pivotal ACTION3 trial of DMX-200 and continue advancing the Phase 2 trial of newly acquired kidney injury treatment DMX-652. The first patients have completed the ACTION3 treatment period and moved into follow-up, while Hugh Alsop has been appointed interim chair following Mark Diamond's retirement.

Comments